Literature DB >> 8636939

Experimental endogenous septicaemia caused by Klebsiella pneumoniae and Escherichia coli in mice.

Y Hirakata1, N Furuya, T Matsumoto, K Tateda, K Yamaguchi.   

Abstract

Multi-resistant Klebsiella pneumoniae have recently occurred in several nosocomial outbreaks of septicaemia. An animal model resembling the pathophysiology of these infections in man would be very useful. A new model of endogenous septicaemia caused by K. pneumoniae and Escherichia coli strains in mice has been established. The mortality rate of conventional ddY mice given cyclophosphamide (CY) or fluorouracil (5-FU), each 200 mg/kg intraperitoneally, every other day was 70 and 100%, respectively. Pseudomonas aeruginosa septicaemia was observed in all dead mice treated with CY, whereas Enterobacteriaceae, including K. pneumoniae, were isolated from 90% of mice given 5-FU. Specific-pathogen-free mice, decontaminated with ampicillin and ceftazidime, were given multi-resistant K. pneumoniae CF504, CF514 or E. coli CF604, or CF614 carrying CAZ-1/TEM-5 plasmid by oral inoculation. Subsequent dosing with 5-FU induced lethal septicaemia caused by the inoculated strains in most of these mice, whereas CY did not regularly induce septicaemia. This model with 5-FU is considered to resemble closely the situation observed in man and to be beneficial for investigating pathophysiology and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636939     DOI: 10.1099/00222615-44-3-211

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  2 in total

Review 1.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

2.  Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals.

Authors:  Maqsood Ahmad; Shazia Akram Ghumman; Alamgeer Sher; Tanveer Sharif; Muhammad Sher; Tahir Abbas
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.